z-logo
open-access-imgOpen Access
Everolimus for the treatment of epithelioid hemangioma: a case report
Author(s) -
Mururul Aisyi,
Ayu Hutami Syarif,
Dewi Aisyah Mukarramah,
Rio Hermawan,
Dewi Iriani
Publication year - 2021
Publication title -
medical journal of indonesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.164
H-Index - 9
eISSN - 2252-8083
pISSN - 0853-1773
DOI - 10.13181/mji.cr.205036
Subject(s) - medicine , everolimus , sclerotherapy , hemangioma , lesion , radiology , surgery , oncology
Epithelioid hemangioma is a rare benign vascular tumor manifested as slow-growing subcutaneous or dermal nodules. A previously therapeutic strategy involved surgical excision and sclerotherapy. However, no standard treatment has been established. Here, we reported an atypical case of epithelioid hemangioma that had a locally aggressive behavior and was successfully treated with everolimus, a rapamycin analog used for cancer therapy. A 1-year-old boy presented with an ulcerated lump in the left palmar region. The imaging test results, confirmed through histopathologic examination, suggested a diagnosis of epithelioid hemangioma. Targeted therapy with everolimus was administered orally because of a minimal response to initial transarterial sclerotherapy. The patient achieved a satisfactory response with a significantly reduced lesion size and improved hand function after a 2-year follow-up. This finding showed that patients with locally aggressive forms of epithelioid hemangioma may significantly benefit from everolimus as a potential targeted therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here